Biotech News

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

Aziyo Biologics (AZYO)Aziyo Biologics2026-05-14 20:06 ESTEarnings

NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant

Aziyo Biologics

Aziyo Biologics is a regenerative medicine company focused on implantable biologic products used in surgery and tissue repair. Its business is centered on specialty biologics rather than classic biotech drug development.

Recent company news

AZYOAziyo Biologics2026-07-31 12:00 EST

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

AZYOAziyo Biologics2026-07-16 20:05 EST

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

AZYOAziyo Biologics2026-06-11 20:05 EST

Elutia to Present at Planet MicroCap Showcase 2026 on June 17th

AZYOAziyo Biologics2026-05-18 20:05 EST

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

AZYOAziyo Biologics2026-05-14 20:06 EST